

Edgar Filing: DYNATRONICS CORP - Form 10QSB

DYNATRONICS CORP
Form 10QSB
February 14, 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-QSB

(Mark One)

QUARTERLY REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
ACT OF 1934

For the quarterly period ended December 31, 2005.

TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE EXCHANGE ACT

For the transition period from _____ to _____

Commission File Number: 0-12697

Dynatronics Corporation

(Exact name of small business issuer as specified in its charter)

Utah

87-0398434

(State or other jurisdiction of
incorporation or organization)

(IRS Employer
Identification No.)

7030 Park Centre Drive, Salt Lake City, UT 84121

(Address of principal executive offices)

(801) 568-7000

(Issuer's telephone number)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

The number of shares outstanding of the issuer's common stock, no par value, as of November 9, 2005 is 9,022,014.

Transitional Small Business Disclosure Format (Check one): Yes No

DYNATRONICS CORPORATION
FORM 10-QSB
DECEMBER 31, 2005
TABLE OF CONTENTS

Page Number

Edgar Filing: DYNATRONICS CORP - Form 10QSB

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements.....	1
Unaudited Balance Sheets	
December 31, 2005 and June 30, 2005.....	1
Unaudited Statements of Operations	
Three and Six Months Ended December 31, 2005 and 2004.....	2
Unaudited Statements of Cash Flows	
Six Months Ended December 31, 2005 and 2004.....	3
Notes to Unaudited Financial Statements.....	4
Item 2. Management's Discussion and Analysis or Plan of Operation.....	9
Item 3. Controls and Procedures.....	16
PART II. OTHER INFORMATION	
Item 6. Exhibits.....	17

DYNATRONICS CORPORATION Balance Sheets

Assets	December 31, 2005 (Unaudited)	June 30, (Audit
	-----	-----
Current assets:		
Cash	\$ 753,279	\$ 4
Trade accounts receivable, less allowance for doubtful accounts of \$262,101 at December 31, 2005 and \$252,509 at June 30, 2005	3,438,434	3,0
Other receivables	77,856	
Inventories, net	4,761,589	4,7
Prepaid expenses	621,021	3
Prepaid income taxes	0	
Deferred tax asset-current	384,077	3
	-----	-----
Total current assets	10,036,256	9,0
Property and equipment, net	3,113,697	3,2
Goodwill, net of accumulated amortization of \$649,792 at December 31, 2005 and at June 30, 2005	789,422	7
Other assets	357,378	3
	-----	-----
	\$ 14,296,753	\$ 13,4
	=====	=====
Liabilities and Stockholders' Equity		
Current liabilities:		
Current installments of long-term debt	\$ 246,456	\$ 2

Edgar Filing: DYNATRONICS CORP - Form 10QSB

Line of credit	270,812	2
Accounts payable	538,908	6
Accrued expenses	548,023	5
Accrued payroll and benefit expenses	268,019	3
Income tax payable	16,632	
	-----	-----
Total current liabilities	1,888,850	2,0
Long-term debt, excluding current installments	2,150,357	1,3
Deferred compensation	374,384	3
Deferred tax liability - noncurrent	223,647	2
	-----	-----
Total liabilities	4,637,238	3,9
	-----	-----
Stockholders' equity:		
Common stock, no par value. Authorized 50,000,000 shares; issued 9,022,014 shares at December 31, 2005 and 9,015,128 shares at June 30, 2005	2,787,095	2,7
Retained earnings	6,872,420	6,7
	-----	-----
Total stockholders' equity	9,659,515	9,5
	-----	-----
	\$ 14,296,753	\$ 13,4
	=====	=====

See accompanying notes to financial statements.

1

DYNATRONICS CORPORATION
Condensed Statements Of Operations
(Unaudited)

	Three Months Ended		
	December 31		
	2005	2004	20
	-----	-----	-----
Net sales	\$ 5,230,833	\$ 5,322,596	\$ 9,58
Cost of sales	3,172,671	3,143,577	5,94
	-----	-----	-----
Gross profit	2,058,162	2,179,019	3,64
	-----	-----	-----
Selling, general, and administrative expenses	1,328,353	1,468,399	2,57
Research and development expenses	432,361	275,364	84
	-----	-----	-----
Operating income	297,448	435,256	22
	-----	-----	-----
Other income (expense):			
Interest income	2,409	929	
Interest expense	(39,880)	(38,612)	(7

Edgar Filing: DYNATRONICS CORP - Form 10QSB

Other income, net	562	975	5
Total other income (expense)	(36,909)	(36,708)	(
Income before income taxes	260,539	398,548	22
Income tax expense	100,306	153,441	8
Net income	\$ 160,233	\$ 245,107	\$ 13
Basic and diluted net income per common share	\$ 0.02	\$ 0.03	\$
Weighted average basic and diluted common shares outstanding (note 2)			
Basic	9,020,394	8,959,180	9,01
Diluted	9,161,516	9,193,826	9,18

2

DYNATRONICS CORPORATION
Statements of Cash Flows
(Unaudited)

	Six Months December 2005

Cash flows from operating activities:	
Net income	\$ 137,912
Adjustments to reconcile net income to net cash provided by operating activities:	
Depreciation and amortization of property and equipment	169,109
Other amortization	3,662
Provision for doubtful accounts	24,000
Provision for inventory obsolescence	126,000
Provision for warranty reserve	129,843
Provision for deferred compensation	13,866
Compensation expense on stock options	0
Change in operating assets and liabilities:	
Receivables	(442,846)
Inventories	(175,066)
Prepaid expenses and other assets	(222,348)
Accounts payable and accrued expenses	(320,788)
Income tax receivable	21,701
Income tax payable	16,632

Net cash (used in) provided by operating	

Edgar Filing: DYNATRONICS CORP - Form 10QSB

activities	(518,323)

Cash flows from investing activities:	
Capital expenditures	(62,362)
Proceeds from sale of assets	1,500

Net cash used in investing activities	(60,862)

Cash flows from financing activities:	
Proceeds from issuance of long-term debt	1,530,000
Principal payments on long-term debt	(684,581)
Net change in line of credit	6,051
Proceeds from issuance of common stock	8,095

Net cash provided by (used in) financing activities	859,565

Net change in cash	280,380
Cash at beginning of period	472,899

Cash at end of period	\$ 753,279
Supplemental disclosures of cash flow information:	
Cash paid for interest	\$ 70,896
Cash paid for income taxes	\$ 48,000
Supplemental disclosure of non-cash investing and financing activities:	
Common stock issued for consulting services	0

See accompanying notes to financial statements.

3

DYNATRONICS CORPORATION
NOTES TO CONDENSED FINANCIAL STATEMENTS
December 31, 2005
(Unaudited)

NOTE 1. PRESENTATION

The financial statements as of December 31, 2005 (unaudited) and June 30, 2005 (audited) and for the three and six months ended December 31, 2005 and 2004 were prepared by the Company without audit pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all necessary adjustments, which consist only of normal recurring adjustments, to the financial statements have been made to present fairly the financial position and results of operations and cash flows. The

Edgar Filing: DYNATRONICS CORP - Form 10QSB

results of operations for the respective periods presented are not necessarily indicative of the results for the respective complete years. The Company has previously filed with the SEC an annual report on Form 10-KSB which included audited financial statements for the two years ended June 30, 2005 and 2004. It is suggested that the financial statements contained in this filing be read in conjunction with the statements and notes thereto contained in the Company's 10-KSB filing.

NOTE 2. NET INCOME PER COMMON SHARE

Net income per common share is computed based on the weighted-average number of common shares and, as appropriate, dilutive common stock equivalents outstanding during the period. Stock options are considered to be common stock equivalents. The computation of diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect.

Basic net income per common share is the amount of net income for the period available to each share of common stock outstanding during the reporting period. Diluted net income per common share is the amount of net income for the period available to each share of common stock outstanding during the reporting period and to each share that would have been outstanding assuming the issuance of common shares for all dilutive potential common shares outstanding during the period.

In calculating net income per common share, the net income was the same for both the basic and diluted calculation for the three and six months ended December 31, 2005. A reconciliation between the basic and diluted weighted-average number of common shares for the three and six months ended December 31, 2005 and 2004 is summarized as follows:

	(Unaudited) Three Months Ended December 31,		(Unaudited) Six Months Ended December 31,
	2005	2004	2005
Basic weighted average number of common shares outstanding during the period	9,020,394	8,959,180	9,019,082
Weighted average number of dilutive common stock options outstanding during the period	141,122	234,646	165,584
Diluted weighted average number of common and common equivalent shares outstanding during the period	9,161,516	9,193,826	9,184,666

NOTE 3. EMPLOYEE STOCK COMPENSATION

The Company employs the footnote disclosure provisions of Statement of Financial Accounting Standard ("SFAS") No. 123, Accounting for Stock-Based Compensation, as amended by SFAS No. 148, Accounting for Stock-Based Compensation - Transition and Disclosure, an amendment of SFAS Statement No. 123. SFAS No. 123 encourages entities to adopt a fair-value-based method of accounting for stock options or similar equity instruments. However, it also allows an entity to continue

Edgar Filing: DYNATRONICS CORP - Form 10QSB

measuring compensation cost for stock-based compensation using the intrinsic-value method of accounting prescribed by Accounting Principles Board (APB) Opinion No. 25, Accounting for Stock Issued to Employees (APB 25). The Company has elected to apply the provisions of APB 25; accordingly, no compensation expense has been recognized for the stock option plan. Had compensation expense for the Company's stock option plan been determined based on the fair value at the grant date for awards consistent with the provisions of SFAS No. 123, the Company's results of operations would have been reduced to the pro forma amounts indicated below:

	Three months ended December 31, 2005	Three months ended December 31, 2004
Net income as reported	\$ 160,233	\$ 160,233
Less: pro forma adjustment for stock based Compensation, net of income tax	(277,912)	(277,912)
Pro forma net income (loss)	\$ (117,679)	\$ (117,679)
Basic net income (loss) per share: As reported	\$ 0.02	\$ 0.02
Effect of pro forma adjustment	(0.03)	(0.03)
Pro forma	(0.01)	(0.01)
Diluted net income (loss) per share: As reported	0.02	0.02
Effect of pro forma adjustment	(0.03)	(0.03)
Pro forma	\$ (0.01)	\$ (0.01)
	Six months ended December 31, 2005	Six months ended December 31, 2004
Net income as reported	\$ 137,912	\$ 137,912
Less: pro forma adjustment for stock based Compensation, net of income tax	(451,474)	(451,474)
Pro forma net income (loss)	\$ (313,562)	\$ (313,562)
Basic net income (loss) per share: As reported	\$ 0.02	\$ 0.02
Effect of pro forma adjustment	(0.05)	(0.05)
Pro forma	(0.03)	(0.03)
Diluted net income (loss) per share: As reported	0.02	0.02
Effect of pro forma adjustment	(0.05)	(0.05)
Pro forma	\$ (0.03)	\$ (0.03)

Edgar Filing: DYNATRONICS CORP - Form 10QSB

The Company granted 446,000 options on May 24, 2005 to officers and employees that had a vesting period of six months and granted 145,000 options on November 22, 2005 to officers and directors that were immediately vested. These vesting periods were substantially shorter in length than previous vesting periods of options granted.

5

The per share weighted-average fair value of stock options granted for the three months ended December 31, 2005 and 2004 was \$1.45 and \$1.16 per share, and for the six months ended December 31, 2005 and 2004 was \$1.59 and \$1.26 per share, respectively, on the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:

	Three months ended December 31, 2005	Three months ended December 31, 2004
Expected dividend yield	0%	0%
Risk-free interest rate	4.37%	3.92%
Expected volatility	87%	88%
Vesting period	0 - 5 years	5 years
Expected life	7 & 10 years	7 years
	Six months ended December 31, 2005	Six months ended December 31, 2004
Expected dividend yield	0%	0%
Risk-free interest rate	4.14 - 4.37%	3.31 - 4.34%
Expected volatility	87 - 88%	87 - 89%
Vesting period	0 - 5 years	1 - 5 years
Expected life	7 & 10 years	5 & 7 years

NOTE 4. COMPREHENSIVE INCOME

For the periods ended December 31, 2005 and 2004, comprehensive income was equal to the net income as presented in the accompanying condensed statements of income.

NOTE 5. INVENTORIES

Inventories consisted of the following:

	December 31, 2005	June 30, 2005
Raw material	\$ 3,052,086	\$ 2,671,255
Finished goods	2,215,137	2,409,435
Inventory reserve	(505,634)	(368,167)
	\$ 4,761,589	4,712,523

NOTE 6. PROPERTY AND EQUIPMENT

Property and equipment were as follows:

December 31, 2005	June 30, 2005

Edgar Filing: DYNATRONICS CORP - Form 10QSB

Land	\$	354,744	\$	354,743
Buildings		2,937,752		2,921,127
Machinery and equipment		1,446,933		1,560,010
Office equipment		1,018,661		1,011,101
Vehicles		94,290		94,290
		-----		-----
		5,852,380		5,941,271
Less accumulated depreciation and amortization		2,738,683		2,719,327
		-----		-----
	\$	3,113,697	\$	3,221,944
		=====		=====

6

NOTE 7. GOODWILL AND INTANGIBLE ASSETS

Goodwill represents the excess of costs over fair value of assets of businesses acquired. The Company adopted the provisions of Statement of Financial Accounting Standards (SFAS) No. 142, Goodwill and Other Intangible Assets, as of July 1, 2002. Goodwill and intangible assets acquired in a purchase business combination and determined to have an indefinite useful life are not amortized, but instead tested for impairment at least annually in accordance with the provisions of SFAS No. 142. Management is primarily responsible for the SFAS No. 142 valuation determination. In compliance with SFAS No. 142, management utilizes standard principles of financial analysis and valuation including: transaction value, market value, and income value methods to arrive at a reasonable estimate of the fair value of the Company in comparison to its book value. The Company has determined it has one reporting unit. As of July 1, 2002, the fair value of the Company exceeded the book value of the Company. Therefore, there was not an indication of impairment upon adoption of SFAS No. 142. Management performed its annual impairment assessment during the Company's fourth quarter ending June 30, 2005 and determined there was not an indication of impairment. SFAS No. 142 also requires that intangible assets with estimable useful lives be amortized over their respective estimated useful lives to their estimated residual values, and reviewed for impairment in accordance with SFAS No. 144, Accounting for Impairment or Disposal of Long-Lived Assets.

Goodwill. As of December 31, 2005, the Company had goodwill, net, of \$789,422 from the acquisition of Superior Orthopaedic Supplies, Inc on May 1, 1996 and the exchange of Dynatronics Laser Corporation common stock for a minority interest in Dynatronics Marketing Corporation on June 30, 1983. Through June 30, 2002, goodwill from these transactions was amortized over a period of 15 and 30 years, respectively, on a straight-line basis.

License Agreement. Identifiable intangible assets consist of a license agreement entered into on August 16, 2000 for a certain concept and process relating to a patent. The license agreement is being amortized over ten years on a straight-line basis. The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of the license agreement:

	As of December 31, 2005	As of June 30, 2005
	-----	-----
Gross carrying amount	\$ 73,240	\$ 73,240
Accumulated amortization	39,062	35,400
	-----	-----

Edgar Filing: DYNATRONICS CORP - Form 10QSB

On December 16, 2004, the Financial Accounting Standards Board ("FASB") published Statement of Financial Accounting Standards No. 123 (Revised 2004), Share Based Payment ("SFAS 123R"). SFAS 123R requires that compensation cost related to share-based payment transactions be recognized in the financial statements. Share-based payment transactions within the scope of SFAS 123R include stock options, restricted stock plans, performance-based awards, stock appreciation rights, and employee share purchase plans. The provisions of SFAS 123R are effective as of the first interim period that begins after December 15, 2005. Accordingly, the Company will implement the revised standard in the third quarter of fiscal year 2006. Currently, the Company accounts for its share-based payment transactions under the provisions of APB 25, which does not necessarily require the recognition of compensation cost in the financial statements. Management is assessing the implications of this revised standard and the effect of the adoption of SFAS 123R will have on our financial position, results of operations, or cash flow.

In March 2005, the Financial Accounting Standard Board ("FASB") issued FASB Interpretation No. 47, "Accounting for Conditional Asset Retirement Obligations" an interpretation of FASB No. 143 ("FIN No. 47"). FIN No. 47 addresses the obligation of a business enterprises to perform an asset retirement activity in which the timing and (or) method of settlement are conditional on a future event that may or may not be within the control of the entity. An entity is required to recognize a liability for the fair value of a conditional asset retirement obligation if the fair value of the liability can be reasonably estimated. The Company evaluated the criteria of this pronouncement and concluded that it has no conditional asset retirement obligation, and therefore the adoption of FIN No. 47 had no impact on the Company's financial statements.

In May 2005, the Financial Accounting Standard Board ("FASB") issued SFAS No. 154, "Accounting Changes and Error Corrections—a replacement of APB Opinion No. 20 and FASB Statement No. 3". This Statement requires retrospective application to prior periods' financial statements of changes in accounting principle, unless it is impracticable to determine the period-specific effects or the cumulative effect of the change. This pronouncement will be effective December 15, 2005. Currently, the Company does not have changes in accounting principle; the adoption of SFAS No. 154 will not impact the Company's financial position or results of operations.

8

Item 2. Management's Discussion and Analysis or Plan of Operation

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the Financial Statements (unaudited) and Notes thereto appearing elsewhere in this report on Form 10-QSB.

Results of Operations

The Company's fiscal year ends on June 30th. This report covers the second quarter ended December 31, 2005, for the Company's fiscal year ending June 30, 2006.

Net Sales

During the quarter ended December 31, 2005, the Company generated sales of \$5,230,833, compared to \$5,322,596 in the quarter ended December 31, 2004. During the six months ended December 31, 2005, the Company generated sales of \$9,589,261, compared to \$10,241,502 in the six months ended December 31, 2004. Second quarter results improved significantly over first quarter results, reflecting solid demand for the Company's new rehab equipment. However, when

Edgar Filing: DYNATRONICS CORP - Form 10QSB

compared to the second quarter and six months of the prior year, the sales increases from new products were offset by lower sales of the Company's aesthetic equipment and older 50 Series products. Reduced sales of aesthetic equipment are primarily attributable to certain dealers deciding to drop high dollar capital equipment from their product offerings. Strategies are being implemented with the intention of restoring these lost sales.

The Company began shipping three new products during the second quarter, including the Dynatron Xp infrared light pad. We believe this innovative product is 14 times more powerful than infrared light probes currently on the market. It is capable of treating a much larger area than can be treated by competitors' devices. Importantly, it makes unattended patient therapy possible, allowing practitioners to treat multiple patients simultaneously. The other two products introduced during the second quarter were the Dynatron iBox iontophoresis device for transdermal drug delivery, and the D880Plus infrared light probe which produces twice the power of its predecessor model.

Gross Profit

During the quarter ended December 31, 2005, total gross profit was \$2,058,162, or 39.3% of net sales, compared to \$2,179,019, or 40.9% of net sales, in the quarter ended December 31, 2004. For the six months ended December 31, 2005, total gross profit was \$3,646,746, or 38.0% of net sales, compared to \$4,190,498, or 40.9% of net sales, in the similar period ended December 31, 2004. The decreases in gross profit as a percent of sales were primarily attributable to reduced sales of older 50 Series therapy devices as well as aesthetic devices which carry above-average margins.

Selling, general and administrative expenses

Selling, general and administrative (SG&A) expenses for the quarter ended December 31, 2005 were \$1,328,353, or 25.4% of net sales, compared to \$1,468,399, or 27.6% of net sales, in the prior year period. SG&A expenses for the six months ended December 31, 2005 were \$2,571,478, or 26.8% of net sales, compared to \$2,955,714, or 28.9% of net sales, in the prior year period.

Total SG&A expenses in the quarter ended December 31, 2005 decreased by \$140,046, or 9.5%, compared to the similar quarter in 2004. The primary components affecting SG&A expenses in the quarter ended December 31, 2005 compared to 2004 were:

- o Approximately \$88,000 in lower labor expenses.
- o Approximately \$78,000 in lower incentive compensation expenses.
- o The reduction in SG&A was partially offset by approximately \$36,000 in increased healthcare insurance premiums.

Total SG&A expenses in the six months ended December 31, 2005 decreased by \$384,236, or 13.0%, compared to the similar period in 2004. The primary components affecting SG&A expenses in the six months ended December 31, 2005 compared to 2004 were:

- o Approximately \$128,000 in lower labor expenses.

9

- o Approximately \$146,000 in lower incentive compensation expenses.
- o Approximately \$91,000 in lower selling expenses primarily related to our aesthetic product line.

Research and Development

Edgar Filing: DYNATRONICS CORP - Form 10QSB

The Company has expanded its R&D capabilities by increasing its staff of engineers in order to develop new products at a more rapid pace. The first of these new products began shipping in October 2005. While this effort has increased short term costs, we believe it will also position the Company to generate future growth in both sales and profits. R&D expenses during the quarter ended December 31, 2005 increased approximately \$157,000 to \$432,361, compared to \$275,364 in the prior year period. R&D expenses during the six months ended December 31, 2005 increased approximately \$316,810 to \$845,965, compared to \$529,155 in the prior year period. R&D expenses represented approximately 8.3% and 5.2% of the net sales of the Company in the quarter and six months ended December 31, 2005, compared to 8.8% and 5.2% of net sales in the 2004 periods, respectively. R&D costs are expensed as incurred.

Pre-tax profit

Pre-tax profit for the quarter ended December 31, 2005 was \$260,539 compared to \$398,548 in the quarter ended December 31, 2004. Pre-tax profit for the six months ended December 31, 2005 was \$224,245 compared to \$641,390 in the six months ended December 31, 2004. Lower sales and margins generated during the reporting quarter and six months periods, combined with higher R&D costs, account for the differences between the comparative periods.

Income Tax

Income tax expense for the quarter ended December 31, 2005 was \$100,306 compared to \$153,441 in the quarter ended December 31, 2004. Income tax expense for the six months ended December 31, 2005 was \$86,333 compared to \$246,935 in the similar period ended December 31, 2004. The effective tax rate for all periods reported was 38.5%.

Net Income

Net income for the quarter ended December 31, 2005 was \$160,233 (approximately \$.02 per share), compared to \$245,107 (approximately \$.03 per share) in the quarter ended December 31, 2004. Net income for the six months ended December 31, 2005 was \$137,912 (approximately \$.02 per share), compared to \$394,455 (approximately \$.04 per share) in the six months ended December 31, 2004. The lower sales and margins generated during the reporting quarter, combined with higher R&D expenses, led to the reduction in net income compared to the prior year periods.

Liquidity and Capital Resources

The Company has financed its operations through cash reserves, available borrowings under its line of credit, and from cash provided by operations. The Company had working capital of \$8,147,406 at December 31, 2005, inclusive of the current portion of long-term obligations and credit facilities, as compared to working capital of \$7,043,854 at June 30, 2005.

Accounts Receivable

Trade accounts receivable, net of allowance for doubtful accounts, increased \$432,119 to \$3,438,434 at December 31, 2005 compared to \$3,006,315 at June 30, 2005. Management anticipates accounts receivable could increase modestly in future periods due to the planned introduction of new products in the second half of fiscal year 2006 which is expected to increase sales.

Trade accounts receivable represent amounts due from the Company's dealer network and from medical practitioners and clinics. We estimate that the allowance for doubtful accounts is adequate based on our historical knowledge and relationship with these customers. Accounts receivable are generally

Edgar Filing: DYNATRONICS CORP - Form 10QSB

collected within 30 days of the agreed terms.

10

Inventories

Inventories, net of reserves, at December 31, 2005 increased \$49,066 to \$4,761,589 compared to \$4,712,523 at June 30, 2005. Management expects that inventories will likely increase during the current fiscal year based on the Company's planned new product introductions.

Prepaid Expenses

Prepaid expenses increased \$234,086 to \$621,021 at December 31, 2005 compared to \$386,935 at June 30, 2005, due primarily to increases in advances made to suppliers for various component parts.

Goodwill

Goodwill at December 31, 2005 and June 30, 2005 was \$789,422. Beginning July 1, 2002, the Company adopted the provisions of SFAS No. 142 Goodwill and other Intangible Assets. In compliance with SFAS 142, management utilized standard principles of financial analysis and valuation including: transaction value, market value and income value methods to arrive at a reasonable estimate of the fair value of the Company in comparison to its book value. The Company has determined it has one reporting unit. As of July 1, 2002 and June 30, 2005, the fair value of the Company exceeded the book value of the Company. Therefore, there was no indication of impairment upon adoption of SFAS No. 142 or at June 30, 2005. Management is primarily responsible for the FAS 142 valuation determination and performed the annual impairment assessment during the Company's fourth quarter.

Accounts Payable

Accounts payable decreased by \$66,880 to \$538,908 at December 31, 2005 compared to \$605,788 at June 30, 2005. The decrease in accounts payable is a result of the timing of our weekly payments to suppliers and the timing of purchases of product components. All accounts payable are within term. We continue to take advantage of available early payment discounts when offered.

Accrued Expenses

Accrued expenses decreased by \$23,917 to \$548,023 at December 31, 2005 compared to \$571,940 at June 30, 2005. Accrued expenses at June 30, 2005 were higher due to the timing of our June 2005 national dealer meeting and accrued expenses for sales incentive programs.

Accrued Payroll & Benefit Expenses

Accrued payroll & benefit expenses decreased by \$100,148 to \$268,019 at December 31, 2005 compared to \$368,167 at June 30, 2005. The decrease in accrued payroll & benefit expenses is related to lower accrued payroll and bonuses for employees, officers, and directors and corresponding payroll taxes.

Cash

The Company's cash position increased \$280,380 to \$753,279 at December 31, 2005 compared to \$472,899 at June 30, 2005. During the quarter ended December 31, 2005, the Company borrowed \$1,530,000, secured by its facility in Tennessee, in order to refinance an existing adjustable rate mortgage and to construct a 10,000 sq. ft. addition to the existing warehouse. The proceeds from the loan

Edgar Filing: DYNATRONICS CORP - Form 10QSB

not used in the refinancing increased the Company's cash position and reduced the outstanding balance on the Company's line of credit. As the Company pays for the construction of the new building, the balance of the loan proceeds will be used, thereby reducing cash balances from current levels. It is anticipated that the construction of the new facility will be completed in February or March 2006.

The Company believes that its current cash balances, amounts available under its line of credit and cash provided by operations will be sufficient to cover its operating needs in the ordinary course of business for the next twelve months. If we experience an adverse operating environment or unusual capital expenditure requirements, additional financing may be required. However, no assurance can be given that additional financing, if required, would be available on favorable terms.

Line of Credit

The Company maintains a revolving line of credit with a commercial bank up to a maximum amount of \$4,500,000. The outstanding balance on our line of credit was \$270,812 at December 31, 2005 compared to \$264,761 at June 30, 2005. Interest on the line of credit is based on the bank's prime rate, which at December 31, 2005, equaled 7.25%. The line of credit is collateralized by accounts receivable

11

and inventories. Borrowing limitations are based on 30% of eligible inventory and up to 80% of eligible accounts receivable. The line of credit is renewable bi-annually on December 1st and includes covenants requiring the Company to maintain certain financial ratios. As of December 31, 2005, the Company was in compliance with all loan covenants.

The current ratio was 5.3 to 1 at December 31, 2005 compared to 4.5 to 1 at June 30, 2005. Current assets represent 70% of total assets at December 31, 2005.

Debt

Long-term debt excluding current installments totaled \$2,150,357 at December 31, 2005 compared to \$1,330,325 at June 30, 2005. During the quarter ended December 31, 2005, the Company borrowed approximately \$1.53 million at a fixed interest rate of 6.4% to refinance its adjustable rate mortgage on the Tennessee facility and construct a 10,000 sq. ft. warehouse at that facility. Long-term debt is comprised primarily of the mortgage loans on our office and manufacturing facilities in Utah and Tennessee. The current principal balance on the mortgage loans is approximately \$2.3 million with monthly principal and interest payments of \$29,006.

Stock Repurchase Program

On September 3, 2003, the Company announced a stock repurchase program. The Board of Directors authorized the expenditure of up to \$500,000 to purchase the Company's common stock on the open market pursuant to regulatory restrictions governing such repurchases. During fiscal 2004, the Company purchased \$89,000 of stock, leaving over \$400,000 of authorized funds for future stock repurchases. The stock repurchase program is conducted pursuant to safe harbor regulations under Rule 10b-18 of the Exchange Act for the repurchase by an issuer of its own shares. No shares were repurchased during the six months ended December 31, 2005.

Stock Options

The Company granted 156,816 stock options to employees, officers and directors

Edgar Filing: DYNATRONICS CORP - Form 10QSB

during the quarter ended December 31, 2005. The options granted to officers and directors were fully vested upon grant. In prior years, the Company has granted options to officers and directors with a vesting period ranging between six months and one year.

Inflation and Seasonality

The Company's revenues and net income from continuing operations have not been unusually affected by inflation or price increases for raw materials and parts from vendors.

The Company's business operations are not materially affected by seasonality factors.

Critical Accounting Policies

We have identified the policies below as critical to our business operations and the understanding of our results of operations. The impact and risks related to these policies on our business operations are discussed in this Management's Discussion and Analysis where such policies affect our reported and expected financial results. For a detailed discussion of the application of these and other accounting policies, see Notes to the Audited Financial Statements contained in the Company's annual report on Form 10-KSB for the year ended June 30, 2005. In all material respects, management believes that the accounting principles that are utilized conform to accounting principles generally accepted in the United States of America.

The preparation of this quarterly report requires us to make significant estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses reported in our unaudited financial statements. By their nature, these judgments are subject to an inherent degree of uncertainty. On an on-going basis, we evaluate these estimates, including those related to bad debts, inventories, intangible assets, warranty obligations, product liability, revenue, and income taxes. We base our estimates on historical experience and other facts and circumstances that are believed to be reasonable, and the results form the basis for making judgments about the carrying value of assets and liabilities. The actual results may differ from these estimates under different assumptions or conditions.

12

Inventory Reserves

The nature of our business requires that we maintain sufficient inventory on hand at all times to meet the requirements of our customers. We record finished goods inventory at the lower of standard cost, which approximates actual costs (first-in, first-out) or market. Raw materials are recorded at the lower of cost (first-in, first-out) or market. Inventory valuation reserves are maintained for the estimated impairment of the inventory. Impairment may be a result of slow moving or excess inventory, product obsolescence or changes in the valuation of the inventory. In determining the adequacy of reserves, we analyze the following, among other things:

- o Current inventory quantities on hand.
- o Product acceptance in the marketplace.
- o Customer demand.
- o Historical sales.
- o Forecast sales.
- o Product obsolescence.
- o Technological innovations.

Edgar Filing: DYNATRONICS CORP - Form 10QSB

Any modifications to estimates of inventory valuation reserves are reflected in the cost of goods sold within the statements of income during the period in which such modifications are determined necessary by management. At December 31, 2005 and June 30, 2005, our inventory valuation reserve balance, which established a new cost basis, was \$505,634 and \$368,167, respectively, and our inventory balance was \$4,761,589 and \$4,712,523 net of reserves, respectively.

Revenue Recognition

Our products are sold primarily to customers who are independent distributors and equipment dealers. These distributors resell the products, typically to end users, including physical therapists, professional trainers, athletic trainers, chiropractors, medical doctors and aestheticians. Sales revenues are recorded when products are shipped FOB shipping point under an agreement with a customer, risk of loss and title have passed to the customer, and collection of any resulting receivable is reasonably assured. Amounts billed for shipping and handling of products are recorded as sales revenue. Costs for shipping and handling of products to customers are recorded as cost of sales.

Allowance for Doubtful Accounts

We must make estimates of the collectibility of accounts receivable. In doing so, we analyze historical bad debt trends, customer credit worthiness, current economic trends and changes in customer payment patterns when evaluating the adequacy of the allowance for doubtful accounts. Our accounts receivable balance was \$3,438,434 and \$3,006,315, net of allowance for doubtful accounts of \$262,101 and \$252,509, at December 31, 2005 and June 30, 2005, respectively.

Business Plan and Outlook

Over the past seven years, annual net sales have grown from \$12.6 million in fiscal year 1998 to \$20.4 million in 2005. During fiscal year 2006, we will continue to focus our efforts on fueling and sustaining growth through the development of new products for the rehabilitation and aesthetics markets while, at the same time, strengthening our channels of distribution and improving operating efficiencies.

The fruits of our focused R&D campaign begun in 2002 were initially manifest in September 2004 when we introduced the Solaris Series, a new product line of advanced technology electrotherapy/ultrasound products featuring an infrared light therapy probe. This new family of products has quickly become our top selling line, due largely to the popularity of infrared light therapy. Light therapy is becoming widely recognized for its successful treatment of painful conditions.

In July 2005, we announced that we would be introducing eight new products over the coming months. The first of those products, the Dynatron Xp Infrared Light Pad and Dynatron XpB, or Booster Box, began shipping to customers in October 2005. The Dynatron Xp Light Pad provides practitioners with a tool that allows unattended therapy of large segments of the body such as the back, thigh or shoulder.

The Dynatron XpB is an accessory that allows the thousands of Solaris unit owners to add the new Xp Infrared Light Pad as an accessory to their existing Solaris device. This compatibility of technology not only opens a significant market segment for the new Xp Infrared Light Pad, but assures users of Dynatronics' products that we are working to make these technologies affordable for them.

Edgar Filing: DYNATRONICS CORP - Form 10QSB

In October 2005, we also began shipping the Dynatron iBox, a new transdermal drug delivery device for iontophoresis that we believe is the most technologically advanced product of its kind on the market. Alone, sales of this device do not contribute significantly. However, the iBox is strategically important in our plans to leverage sales of the iontophoresis electrodes we distribute. Over the coming six to twelve months, we intend to introduce a new iontophoresis electrode program that will utilize the iBox device as a focal point of this strategy.

In January 2006, we began shipping the Dynatron 702, a stand-alone light therapy device that not only simplifies infrared light therapy treatments, but can be combined with our traction device for dual traction and light therapy treatments. The original Solaris series devices offered light therapy as an added accessory to our popular combination electrotherapy/ultrasound technology. However, there has been increasing market demand for a stand-alone unit.

The probes being offered with the Dynatron 702 include not only the Dynatron 880 and 890 probes, but also two new probes - the D880Plus which generates twice the power output of its predecessor model, and the D405 which produces a combination infrared and blue wavelength output.

In January 2006, we also introduced the DX9 combination traction and light therapy system. We believe that combining the pain relieving characteristics of infrared light therapy as offered through our new Xp Light Pad, with the traditional benefits of decompression therapy through traction, will make our DX9 traction system one of the most unique products of its kind on the market. It is designed to provide practitioners a more effective way to relieve pain using combination therapy. The DX9 package is a combination of the new Dynatron 702 device, our existing Dynatron TX900 Traction Device, and a revised version of our HLT4 Traction table, together with key accessories to accommodate decompression therapy.

We anticipate introducing the following new products and product combinations before the end of the fiscal year or shortly thereafter:

- o Dynatron X3 - This is a multi-channel infrared light therapy device. It will be capable of accommodating two Xp Infrared Light Pads as well as the practitioner's choice of probe. It will incorporate touch screen technology for easy interface with the practitioner.
- o Dynatron DX2 - This device is a combination traction and infrared light therapy device. It will be Dynatronics' first proprietary traction device and will incorporate not only touch screen technology, but other unique and proprietary technology that will facilitate traction and decompression therapy. It will be the only unit on the market that offers traction and infrared light therapy from the same device.
- o T4 Therapy Table - The T4 therapy table is designed to be used specifically in traction and decompression therapy. It will offer unique features that more fully accommodate the delivery of traction and decompression therapy.
- o DX1 package - The DX1 will combine the DX2 and the T4 table in a package along with additional accessories needed for decompression therapy.

Another important part of our strategic plan is the further expansion of worldwide marketing efforts. Over the past two years, international sales have doubled to approximately 6% of net sales and we continue to press forward seeking additional opportunities for international expansion. The Company's Salt Lake City operation, where all electrotherapy, ultrasound, STS devices, light

Edgar Filing: DYNATRONICS CORP - Form 10QSB

therapy and Synergie products are manufactured, is certified to ISO 13485, an internationally recognized standard of excellence in medical device manufacturing. This designation is an important requirement in obtaining the CE Mark certification, which allows us to market our products in the European Union and other foreign countries.

We continue efforts to promote our line of aesthetic equipment which includes the Synergie AMS device for dermal massage, the Synergie MDA device for microdermabrasion, and the Synergie LT device, an infrared light therapy unit designed specifically for aesthetic applications. We plan to develop and introduce additional light therapy devices for the aesthetic market. Recent interest by medical spas in the use of other physical therapy modalities such as electrotherapy, ultrasound and light therapy in aesthetic applications has opened new potential for crossover of physical medicine modalities into the aesthetics market. This presents a unique opportunity for us to grow sales of new aesthetic products with little additional R&D effort since the products have already been developed for the physical medicine markets. We are also considering new methods of distribution to boost sales that have lagged due to reduced dealer interest in capital equipment.

14

Based on our defined strategic initiatives, we are focusing our resources in the following areas:

- o Reinforcing our position in the physical medicine market through an aggressive research and development campaign that will result in the introduction of a record number of new products, both high tech and commodity, in fiscal year 2006.
- o Increasing sales of Solaris devices through the introduction of new light therapy accessories and by developing new markets for light therapy applications.
- o Improving sales and distribution of rehabilitation products domestically through strengthened relationships with dealers, particularly the high-volume specialty dealers.
- o Improving distribution of aesthetic products domestically and exploring the opportunities to introduce more light therapy devices and versions of our physical therapy modalities into the aesthetics market.
- o Expanding distribution of both rehabilitation and aesthetic products internationally.
- o Seeking strategic partnerships to further expand our presence in and market share of the physical rehabilitation and the aesthetics markets.

Cautionary Statement Concerning Forward-Looking Statements

The statements contained in this report on Form 10-QSB, particularly the foregoing discussion in Part 1 Item 2, Management's Discussion and Analysis or Plan of Operation, that are not purely historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act. These statements refer to our expectations, hopes, beliefs, anticipations, commitments, intentions and strategies regarding the future. They may be identified by the use of the words or phrases "believes," "expects," "anticipates," "should," "plans," "estimates," "intends," and "potential," among

Edgar Filing: DYNATRONICS CORP - Form 10QSB

others. Forward-looking statements include, but are not limited to, statements contained in Management's Discussion and Analysis or Plan of Operation regarding product development, market acceptance, financial performance, revenue and expense levels in the future and the sufficiency of its existing assets to fund future operations and capital spending needs. Actual results could differ materially from the anticipated results or other expectations expressed in such forward-looking statements for the reasons detailed in our Annual Report on Form 10-KSB under the headings "Description of Business" and "Risk Factors." The fact that some of the risk factors may be the same or similar to past reports filed with the Securities and Exchange Commission means only that the risks are present in multiple periods. We believe that many of the risks detailed here and in our other SEC filings are part of doing business in the industry in which we operate and compete and will likely be present in all periods reported. The fact that certain risks are endemic to the industry does not lessen their significance.

The forward-looking statements contained in this report are made as of the date of this report and we assume no obligation to update them or to update the reasons why actual results could differ from those projected in such forward-looking statements. Among others, risks and uncertainties that may affect the business, financial condition, performance, development, and results of operations include:

- o Market acceptance of our technologies, particularly our core therapy devices, Synergie AMS/MDA product line, and the Solaris infrared light therapy products;
- o Failure to timely release new products against market expectations;
- o The ability to hire and retain the services of trained personnel at cost-effective rates;
- o Rigorous government scrutiny or the possibility of additional government regulation of the industry in which we market our products;
- o Reliance on key management personnel;
- o Foreign government regulation of our products and manufacturing practices that may bar or significantly increase the expense of expanding to foreign markets;
- o Economic and political risks related to expansion into international markets;

15

- o Failure to sustain or manage growth including the failure to continue to develop new products or to meet demand for existing products;
- o Reliance on information technology;
- o The timing and extent of research and development expenses;
- o The ability to keep pace with technological advances, which can occur rapidly;
- o The loss of product market share to competitors;

Edgar Filing: DYNATRONICS CORP - Form 10QSB

- o Potential adverse effect of taxation;
- o Additional terrorist attacks on U.S. interests and businesses;
- o The ability to obtain required financing to meet changes or other risks; and
- o Escalating costs of raw materials, particularly steel and petroleum based materials.

As a public company, we are subject to the reporting requirements of the Securities Exchange Act of 1934 and the Sarbanes-Oxley Act of 2002. These requirements may place a strain on our systems and resources. The Securities Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and financial condition. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal controls over financial reporting. We are currently reviewing and further documenting our internal control procedures. However, the guidelines for the evaluation and attestation of internal control systems have only recently been finalized, and the evaluation and attestation processes are new and untested. Therefore, we can give no assurances that our systems will satisfy the new regulatory requirements. In addition, in order to maintain and improve the effectiveness of our disclosure controls and procedures and internal controls over financial reporting, significant resources and management oversight will be required.

Item 3. Controls and Procedures

Based on evaluation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act), as of the end of the period covered by this Report, our principal executive and principal financial officers have concluded that our disclosure controls and procedures are effective at the reasonable assurance level. There were no changes in our internal control over financial reporting that occurred during the quarter ended December 31, 2005 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 4. Submission of Matters to a Vote of Security Holders

At the company's Annual Meeting of Shareholders held on November 22, 2005, the shareholders of the company voted on the following proposals:

Proposal 1 - To elect six directors, each to serve until the next annual meeting of shareholders and until his successor is elected and shall have qualified. Those nominated were all currently serving as directors of the company, i.e., Kelvyn H. Cullimore, Jr., Larry K. Beardall, E. Keith Hansen MD, Howard L. Edwards, Joseph H. Barton and Val J. Christensen.

Proposal 2 - To approve the proposed 2005 Equity Incentive Award Plan.

Proposal 3 - To approve the Audit Committee's selection of Tanner LC as the company's independent auditors for the year ending June 30, 2006.

Each of the proposals was approved by the requisite majority of the shares cast at the annual meeting. The following table summarizes the voting results:

Edgar Filing: DYNATRONICS CORP - Form 10QSB

	For	Against	Abstain
Proposal 1: -----			
Mr. Cullimore, Jr.	7,314,610	34,285	139,292
Mr. Beardall	7,338,765	10,130	139,292
Dr. Hansen	7,342,865	6,030	139,292
Mr. Christensen	7,334,302	14,593	139,292
Mr. Barton	7,327,432	21,463	139,292
Mr. Edwards	7,335,965	12,930	139,292

	For	Against	Abstain
Proposal 2*: -----			
	1,810,269	426,435	59,850

* Excludes 5.2 million broker non-votes

	For	Against	Abstain
Proposal 3: -----			
	7,400,163	42,569	45,455

Item 6. Exhibits

(a) Exhibits

- 3.1 Articles of Incorporation and Bylaws of Dynatronics Laser Corporation. Incorporated by reference to a Registration Statement on Form S-1 (No. 2-85045) filed with the Securities and Exchange Commission and effective November 2, 1984, as amended by Articles of Amendment dated November 18, 1993.
- 3.2 Articles of Amendment dated November 21, 1988 (previously filed).
- 10.1 Employment contract with Kelvyn H. Cullimore, Jr. (previously filed)
- 10.2 Employment contract with Larry K. Beardall (previously filed)
- 10.3 Loan Agreement with Zions Bank (previously filed)
- 10.5 Amended Loan Agreement with Zions Bank (previously filed)
- 10.6 1992 Amended and Restated Stock Option Plan (previously filed)
- 10.7 Dynatronics Corporation 2005 Equity Incentive Award Plan (previously filed as Annex A to the Company's Definitive Proxy Statement on Schedule 14A filed on October 27, 2005)
- 11 Computation of Net Income per Share (included in Notes to Consolidated Financial Statements)
- 31.1 Certification under Rule 13a-14(a)/15d-14(a) of principal executive officer (filed herewith)
- 31.2 Certification under Rule 13a-14(a)/15d-14(a) of principal financial officer (filed herewith)

Edgar Filing: DYNATRONICS CORP - Form 10QSB

32 Certification under Section 906 of the Sarbanes-Oxley Act
of 2002 (18 U.S.C. SECTION 1350) (filed herewith)

17

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

DYNATRONICS CORPORATION
Registrant

Date 2/13/05 /s/ Kelvyn H. Cullimore, Jr.

Kelvyn H. Cullimore, Jr.
Chairman, President and Chief Executive
Officer
(Duly Authorized Officer and
Principal Executive Officer)

Date 2/13/05 /s/ Terry M. Atkinson, CPA

Terry M. Atkinson, CPA
Chief Financial Officer
(Principal Financial Officer)

18